Navigation Links
Keystone Nano Announces Progress On RNA Delivery
Date:4/11/2017

STATE COLLEGE, Pa., April 11, 2017 /PRNewswire/ -- Keystone Nano, Inc. (KN), a clinical stage biopharmaceutical company focused on improving cancer treatments through the application of nanotechnology, announced today significant progress on the delivery of RNA using NanoJackets (NJs).  KN's NanoJackets are proprietary, customizable calcium phosphate nanoparticles that protect the active agent in the bloodstream and deliver it to targeted cells.  Key recent achievements include:

  • substantial new knowledge on encapsulating various kinds of RNA including siRNA, micro RNA and messenger RNA,
  • improved knowledge about the safety/toxicity of the NanoJacketed RNA,
  • new understanding of bio-distribution after administration by injection or inhalation, and
  • greater knowledge about the length of time RNA-NanoJackets work within the body

KN is working to optimize the therapeutic activity of RNA both for the internal programs and for pharmaceutical client companies.  KN has found that working with NanoJackets to encapsulate and deliver the different types of RNA requires different approaches for each.  However, in all cases, KN's RNA-NanoJackets have shown that they contain substantial amounts of RNA, are composed of safe and well tolerated materials, protect the RNA from degradation in the blood stream and can be targeted to specific cell types.

Several new breakthrough therapies anticipate using the different types of RNA to halt disease progression – either by silencing select RNA processes associated with disease, or by using RNA to code for production of therapeutic molecules within the body itself.  The increasing interest in RNA therapy has led to a need for a safe, effective and efficient method to deliver RNA.  KN's calcium phosphate NanoJackets offer a highly biocompatible, non-toxic and effective solution to that problem.

KN's work in RNA delivery has been supported by grants from the National Cancer Institute, the National Institute for Allergies and Infectious Diseases, and the Pennsylvania Department of Health.  KN's work in RNA delivery builds on work at Penn State and the University of Virginia. Jeff Davidson, KN's CEO, noted: "our research team has made great progress building powerful new ways to deliver RNA.  Our goal is to continue this work to further improve human health."

About Keystone Nano, Inc.  KNs lead product, Ceramide NanoLiposome, entered clinical testing in early 2017.  For more information visit www.keystonenano.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/keystone-nano-announces-progress-on-rna-delivery-300437963.html


'/>"/>
SOURCE Keystone Nano, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Keystone Nano Announces Start Of Clinical Testing Of Ceramide NanoLiposome For The Improved Treatment Of Cancer
2. Applied BioMath, LLC presents work in immuno-oncology and antibody drug-conjugates at Keystone Symposium
3. MaxCyte, Inc. to Present Pre-Clinical Data for Targeted Gene-Correction in a Rare Disease at Keystone Symposia on Precision Genome Engineering
4. University City Keystone Innovation Zone Expands to Old City, N3rd Street Startup Community
5. Keystone Symposia Announces Grant from Alfred P. Sloan Foundation for an Advanced Life Sciences Training Program
6. Greater Gift Initiative Announces Partnership with INC Research
7. Axovant Sciences Ltd. Announces $100 Million Public Offering of Common Shares
8. Bioptix Announces Executive Leadership Change
9. Nerium International announces expansion into New Zealand
10. Charm Sciences Announces New Sales/Business Manager
11. BIOARRAY Genetics Inc. Announces the Launch of a Novel Oncology Gene Panel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/9/2018)... ... August 08, 2018 , ... ... was developed and is continually updated by a talented scientific team that includes ... service provides: , 1. Information on the medical impact of a patient’s ...
(Date:8/9/2018)... ... August 09, 2018 , ... Simpson ... construction (AEC) experts with building owners and managers for a full-day discussion on ... Construct symposium comes to Boston for the first time on Thursday, 13 September ...
(Date:7/31/2018)... (PRWEB) , ... July 31, 2018 , ... ... 2 additional CE/IVD marked molecular quality controls to its expanding CE/IVD product inventory. ... controls to our expanding CE/IVD QC offerings. ZeptoMetrix remains entirely committed to fully ...
(Date:7/25/2018)... ... July 25, 2018 , ... Dimitrius Anagnos, an evidence-based ... combat inflammation and autoimmune disorders. , The preclinical research assessed biomarkers for ... was reported:, Over 70% decrease in Interleukin (IL-1ß) ...
Breaking Biology Technology:
(Date:8/2/2018)... ... August 02, 2018 , ... ... health innovator Boston Heart Diagnostics to its Lifestyle Medicine Corporate Roundtable, a group ... health care system and a sustainable world. , Boston Heart is transforming ...
(Date:8/1/2018)... ... July 31, 2018 , ... ... Awards at Global Conference , Awards honor late founder of Wisdom National Brands® ... National Brands, presented prestigious stevia awards to a renowned German professor and a ...
(Date:7/31/2018)... and CARLSBAD, Calif. (PRWEB) , ... July 31, 2018 , ... ... software to connect seamlessly with LabArchives , the leading cloud-based Electronic Lab ... biology procedures and LabArchives enables researchers to store all of their research data records ...
Breaking Biology News(10 mins):